Peregrine Capital Management LLC Buys Shares of 311,224 Artivion, Inc. (NYSE:AORT)

Peregrine Capital Management LLC purchased a new position in Artivion, Inc. (NYSE:AORT - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 311,224 shares of the company's stock, valued at approximately $7,650,000. Peregrine Capital Management LLC owned 0.73% of Artivion at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AORT. Legacy Advisors LLC purchased a new position in shares of Artivion during the first quarter valued at about $28,000. Smartleaf Asset Management LLC lifted its holdings in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after acquiring an additional 786 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Artivion in the fourth quarter worth about $64,000. KLP Kapitalforvaltning AS bought a new stake in Artivion during the fourth quarter worth approximately $194,000. Finally, Raymond James Financial Inc. purchased a new stake in Artivion during the fourth quarter valued at approximately $275,000. Institutional investors own 86.37% of the company's stock.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Jean F. Holloway sold 8,748 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total value of $253,692.00. Following the transaction, the senior vice president directly owned 178,510 shares in the company, valued at $5,176,790. This represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Marshall S. Stanton sold 15,000 shares of Artivion stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $29.50, for a total transaction of $442,500.00. Following the sale, the senior vice president directly owned 64,200 shares of the company's stock, valued at $1,893,900. This represents a 18.94% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,954 shares of company stock valued at $2,108,525 in the last three months. Company insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Finally, Canaccord Genuity Group initiated coverage on shares of Artivion in a report on Tuesday, June 17th. They issued a "buy" rating and a $35.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Artivion currently has an average rating of "Buy" and an average price target of $32.40.

Artivion Trading Down 0.4%

Shares of AORT stock traded down $0.13 on Friday, reaching $30.72. 118,113 shares of the company's stock were exchanged, compared to its average volume of 337,464. The company's fifty day simple moving average is $28.59 and its 200 day simple moving average is $27.57. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $32.33. The company has a current ratio of 5.53, a quick ratio of 3.95 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $1.31 billion, a PE ratio of -61.44 and a beta of 1.62.

Artivion (NYSE:AORT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). The business had revenue of $98.98 million for the quarter, compared to the consensus estimate of $94.81 million. Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. As a group, analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.